mRNA therapeutics have emerged as a revolutionary force in medicine, riding the wave of success initially generated by mRNA vaccines for COVID-19. However, as the field progresses from vaccines to protein replacement therapies and beyond, it faces distinct hurdles,...
Collaboration expands Areterna’s reach in Europe and strengthens Biomay’s mRNA CDMO offerings. Gaithersburg, MD and Vienna, Austria (September 18, 2024) — Areterna LLC, a company with a mission to democratize mRNA products by supplying low-cost GMP raw materials,...
Synthgene Biotechnology, Areterna’s parent company, has been a leading producer of GMP-grade cap analogs, NTPs, and modified NTPs for several years, establishing a strong reputation for quality and reliability in the industry. Our raw materials play a crucial...
Recently, Synthgene Biotech (hereinafter referred to as “Synthgene”), Areterna’s parent company, received a confirmation letter from the United States Food and Drug Administration (FDA) for one of our core mRNA raw material products – CAP5 – which have...
FOR IMMEDIATE RELEASE Gaithersburg, MD (July 2nd, 2024) — Areterna LLC, a company with a mission to democratize mRNA vaccine by supplying low-cost GMP raw materials, today announced plans to offer veterinary mRNA vaccine development service to its customers in the US...
